Search Results - "Glover, Rebecca A."

  • Showing 1 - 20 results of 20
Refine Results
  1. 1

    MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer by Rokhlin, Oskar W, Scheinker, Vladimir S, Taghiyev, Agshin F, Bumcrot, David, Glover, Rebecca A, Cohen, Michael B.

    Published in Cancer biology & therapy (01-08-2008)
    “…We investigated whether knocking down AR expression effects apoptosis after treatment with different apoptosis-inducing agents. We found that siRNA AR (si-AR)…”
    Get full text
    Journal Article
  2. 2

    TOFA (5-tetradecyl-oxy-2-furoic acid) reduces fatty acid synthesis, inhibits expression of AR, neuropilin-1 and Mcl-1 and kills prostate cancer cells independent of p53 status by Guseva, Natalya V., Rokhlin, Oskar W., Glover, Rebecca A., Cohen, Michael B.

    Published in Cancer biology & therapy (01-07-2011)
    “…A key player in prostate cancer development and progression is the androgen receptor (AR). Tumor-associated lipogenesis can protect cancer cells from…”
    Get full text
    Journal Article
  3. 3

    Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival by Rokhlin, Oskar, Taghiyev, Agshin F., Bayer, K. Ulrich, Bumcrot, David, Kotelianski, Victor E, Glover, Rebecca A., Cohen, Michael B.

    Published in Cancer biology & therapy (01-05-2007)
    “…It has recently been shown that the androgen receptor (AR) is the main factor that required for prostate cancer cells survival. We show that knocking down AR…”
    Get full text
    Journal Article
  4. 4

    P53 and the proteasome regulate androgen receptor activity by Guseva, Natalya V., Rokhlin, Oskar W., Glover, Rebecca A., Cohen, Michael B.

    Published in Cancer biology & therapy (01-05-2012)
    “…Mutual regulation of expression between p53 and AR has been reported. To further investigate the role of p53 in the regulation of AR expression, an…”
    Get full text
    Journal Article
  5. 5

    KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer by Rokhlin, Oskar, Guseva, Natalya V., Taghiyev, Agshin F., Glover, Rebecca A., Cohen, Michael B.

    Published in Cancer biology & therapy (01-02-2010)
    “…It has been suggested that the down-regulation of AR expression should be considered the principal strategy for the treatment of hormone-refractory prostate…”
    Get full text
    Journal Article
  6. 6

    Bisindolylmaleimide IX Facilitates Tumor Necrosis Factor Receptor Family-mediated Cell Death and Acts as an Inhibitor of Transcription by Rokhlin, Oskar W., Glover, Rebecca A., Taghiyev, Agshin F., Guseva, Natalya V., Seftor, Richard E.B., Shyshynova, Inna, Gudkov, Andrei V., Cohen, Michael B.

    Published in The Journal of biological chemistry (06-09-2002)
    “…Bisindolylmaleimides (Bis) were originally described as protein kinase C inhibitors. Several studies have shown that Bis potentiate tumor necrosis factor (TNF)…”
    Get full text
    Journal Article
  7. 7

    Generation and Validation of Monoclonal Antibodies Against the Maltose Binding Protein by Park, Yang-Nim, Glover, Rebecca A, Daniels, Karla J, Soll, David R

    “…The maltose binding protein (MBP) is a commonly used protein tag. Two monoclonal antibodies (mAbs) were generated against the MBP by immunizing mice with…”
    Get more information
    Journal Article
  8. 8

    Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP by ROKHLIN, Oskar W, TAGHIYEV, Agshin F, GUSEVA, Natalya V, GLOVER, Rebecca A, CHUMAKOV, Peter M, KRAVCHENKO, Julia E, COHEN, Michael B

    Published in Oncogene (13-10-2005)
    “…It has been suggested in many studies that combined treatment with chemotherapeutic agents and apoptosis-inducing ligands belonging to TNFR family is a more…”
    Get full text
    Journal Article
  9. 9

    Fas-mediated apoptosis in human prostatic carcinoma cell lines by ROKHLIN, O. W, BISHOP, G. A, HOSTAGER, B. S, WALDSCHMIDT, T. J, SIDORENKO, S. P, PAVLOFF, N, KIEFER, M. C, UMANSKY, S. R, GLOVER, R. A, COHEN, M. B

    Published in Cancer research (Chicago, Ill.) (01-05-1997)
    “…Of six prostatic carcinoma cell lines examined (ALVA31, DU145, JCA1, LNCaP, ND1, and PC3) by flow cytometric analysis, all were found to be positive for Fas…”
    Get full text
    Journal Article
  10. 10

    TSA-induced cell death in prostate cancer cell lines is caspase-2 dependent and involves the PIDDosome by Taghiyev, Agshin F, Guseva, Natalya V, Glover, Rebecca A, Rokhlin, Oskar W, Cohen, Michael B

    Published in Cancer biology & therapy (01-09-2006)
    “…The histone deacetylase inhibitor Trichostatin A (TSA) has previously been found to induce caspase activity in the human prostate cancer cell line DU145 and…”
    Get full text
    Journal Article
  11. 11

    Fas-mediated apoptosis in human prostatic carcinoma cell lines occurs via activation of caspase-8 and caspase-7 by ROKHLIN, O. W, GLOVER, R. A, COHEN, M. B

    Published in Cancer research (Chicago, Ill.) (15-12-1998)
    “…We previously demonstrated that treatment with cycloheximide (CHX) converted the phenotype of Fas-resistant human prostatic carcinoma cell lines to…”
    Get full text
    Journal Article
  12. 12

    Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP by Rokhlin, Oskar W., Guseva, Natalya V., Tagiyev, Agshin F., Glover, Rebecca A., Cohen, Michael B.

    Published in The Prostate (01-06-2002)
    “…BACKGROUND The differential sensitivity of tumor cells to TRAIL‐induced apoptosis may be mediated by different intracellular inhibitors of apoptosis, and only…”
    Get full text
    Journal Article
  13. 13

    p53 is involved in tumor necrosis factor-α-induced apoptosis in the human prostatic carcinoma cell line LNCaP by ROKHLIN, O. W, GUDKOV, A. V, KWEK, S, GLOVER, R. A, GEWIES, A. S, COHEN, M. B

    Published in Oncogene (06-04-2000)
    “…The human prostatic carcinoma cell line LNCaP is sensitive to TNF-alpha treatment and expresses wild-type p53. To analyse the possible role of p53 in…”
    Get full text
    Journal Article
  14. 14

    Multiple effects of N-alpha-tosyl-L-phenylalanyl chloromethyl ketone (TPCK) on apoptotic pathways in human prostatic carcinoma cell lines by Rokhlin, Oskar W, Guseva, Natalya V, Taghiyev, Agshin F, Glover, Rebecca A, Cohen, Michael B

    Published in Cancer biology & therapy (01-08-2004)
    “…TPCK is widely used as an inhibitor of chymotrypsin-like proteases but has recently been identified as an inhibitor of the PDK1/Akt pathway. In this study, we…”
    Get full text
    Journal Article
  15. 15

    TRAIL-DISC Formation Is Androgen-Dependent in the Human Prostatic Carcinoma Cell Line LNCaP by Rokhlin, Oskar W, Taghiyev, Agshin F., Guseva, Nataliya V., Glover, Rebecca A., Syrbu, Sergei I., Cohen, Michael B.

    Published in Cancer biology & therapy (01-11-2002)
    “…We and others have previously described that the androgen-responsive human prostatic carcinoma cell line LNCaP is resistant to TRAIL and that TRAIL-mediated…”
    Get full text
    Journal Article
  16. 16

    Multiple effects of N-a-tosyl-L-phenylalanyl chloromethyl ketone (TPCK) on apoptotic pathways in human prostatic carcinoma cell lines by Rokhlin, Oskar W., Guseva, Natalya V., Taghiyev, Agshin F., Glover, Rebecca A., Cohen, Michael B.

    Published in Cancer biology & therapy (01-08-2004)
    “…TPCK is widely used as an inhibitor of chymotrypsin-like proteases but has recently been identified as an inhibitor of the PDK1/Akt pathway. In this study, we…”
    Get full text
    Journal Article
  17. 17
  18. 18

    TRAIL-DISC Formation Is Androgen-Dependent in the Human Prostatic Carcinoma Cell Line LNCaP by Michael B. Cohen, Oskar W Rokhlin, Rebecca A. Glover, Nataliya V. Guseva, Agshin F. Taghiyev, Sergei I. Syrbu

    Published in Cancer biology & therapy (01-11-2002)
    “…We and others have previously described that the androgen-responsive human prostatic carcinoma cell line LNCaP is resistant to TRAIL and that TRAIL-mediated…”
    Get full text
    Journal Article
  19. 19

    p53 is involved in tumor necrosis factor-[alpha]-induced apoptosis in the human prostatic carcinoma cell line LNCaP by Rokhlin, Oskar W, Gudkov, Andrei V, Kwek, Serena, Glover, Rebecca A, Gewies, Andreas S, Cohen, Michael B

    Published in Oncogene (06-04-2000)
    “…The human prostatic carcinoma cell line LNCaP is sensitive to TNF-alpha treatment and expresses wild-type p53. To analyse the possible role of p53 in…”
    Get full text
    Journal Article
  20. 20

    Dominant nature of the resistance to Fas- and tumor necrosis factor-α-mediated apoptosis in human prostatic carcinoma cell lines by ROKHLIN, O. W, HOSTAGER, B. S, BISHOP, G. A, SIDORENKO, S. P, GLOVER, R. A, GUDKOV, A. V, COHEN, M. B

    Published in Cancer research (Chicago, Ill.) (15-09-1997)
    “…We have recently found (O. W. Rokhlin et al., Cancer Res., 57: 1758-1768, 1997) that, although Fas ligation induced apoptosis in two of six human prostatic…”
    Get full text
    Journal Article